QualityStocksNewsBreaks – VolitionRx Ltd. (NYSE American: VNRX) Reports Finger-Prick Breakthrough for Nucleosome Detection in Sepsis
VolitionRx Limited (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced a technical milestone with the successful detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples. The findings also support the feasibility of early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings. The company said the prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established…
